Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Eli Lilly's antibody cuts risk of Covid-19 by up to 80% among the most vulnerable — but will it have a place next to vaccines?

2 hours ago

Endpoints poll: Janet Woodcock takes the (interim) helm at the FDA. And a large majority of our readers want her to ...

3 hours ago

What’s next for Endpoints — and how to support our independent biopharma news mission

3 hours ago

Publisher's note

Northway Biotech sets up shop in Boston hub, looking to court more customers with biologics-focused plant

26 minutes ago

Latest

Most read

GlaxoSmithKline's $4B bispecific cancer drug alliance with Merck KGaA hit by big setback with a PhIII failure on ...

Yesterday

News briefing: Five public biotechs, over 2 days, raise $883M from fresh offerings; Belgian biotech expands Series B ...

27 minutes ago

Covid-19 roundup: Italy wonders aloud if it can sue Pfizer for vaccine shortfalls; Flood, deadly fire threaten ...

2 hours ago

Plexium adds industry vet Mike Grey to the brain trust with new investor cash funding its protein degradation play

2 hours ago

With patent concerns looming, Roche gets a new priority review on blockbuster IPF drug

3 hours ago

BIO looks to restructure, laying off staff amid challenge to the trade org's normal face-to-face style

3 hours ago

see latest stream

People

As he wraps stormy FDA tenure, Hahn admits 'there was a substantial amount of pressure' from White House — report

Yesterday

Gilead's Kite recruits an AbbVie/NIH veteran to head up cell therapy R&D. And he's taking aim at AML in a ferociously ...

2 days ago

Biden elevates White House science office to Cabinet-level, with geneticist Eric Lander put forward to lead policy

2 days ago

Financing

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq

Yesterday

The IPO queue adds 5 more biotechs hoping to ring in 2021 by blitzing Nasdaq

Yesterday

'Bluest of blue-chip investors' pump $94M into Sekar Kathiresan's quest to bring CRISPR to the heart

2 days ago

Startups

UPDATED: An ambitious GV-backed gene editing upstart re-emerges as a one-drug kidney company

2 days ago

A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic

Last week

Flagship christens the latest startup to join the drug discovery fleet, this time focused on the lessons of cell ...

Last week

Deals

Once laser-focused on liver, MiNA takes swing at neurology with Servier's backing

5 hours ago

Gritstone continues Covid-19 push with deal to develop 'self-amplifying RNA' vaccines, as shares continue ballooning

Yesterday

Lonza hits the exit on gel and liquid capsules, offloading 2 production sites to NextPharma

2 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

As coronavirus variants trigger new alarms, the NIH is putting an under-the-radar ‘next-gen’ vaccine into PhI

2 days ago

Pssst: That big Biohaven Alzheimer's study? It was a bust. Even the subgroup analysis execs touted was a flop

2 days ago

Painting by the numbers, Sana founders carve up a giant unicorn-sized IPO — for a biotech that hasn't quite made it ...

Last week

With a torrent of venture cash gushing from a global pack of unicorn hunters, this biotech founder vows to stay ...

Last week

Don't missSee all

Covid-19 claims another PDUFA victim as GlaxoSmithKline pushes back planned PD-1 rollout

Yesterday

Covid-19 roundup: BioNTech offers data showing Pfizer-partnered vaccine protects against variant; Novavax attributes ...

Yesterday

Merck makes good on big CV gamble with vericiguat nod — but competition will be fierce

Yesterday

Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

2 days ago

Endpoints Standouts

2020’s NDA list is packed with commercial firsts — from historic to haphazard. Have we reached a tipping point?

3 weeks ago

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

Last month

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

3 months ago

The 20 under 40: Inside the next generation of biopharma leaders

9 months ago

Peer review See all

Jan

15

NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna's chief safety officer

Jan

8

Alkermes promotes from within to find new CFO and COO in rebound effort; Moderna vet Robert Dolski joins Checkmate as ...

Dec

23

Alnylam bids adieu to 2020 — and hello to a slate of new execs; Novavax taps Rick Crowley as COO

Dec

18

Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from ...

Dec

11

Global Blood Therapeutics recruits a CHOP sickle cell expert as R&D chief; Catalent plucks Janssen vet to head new ...

Pharma channel feed

Yesterday

BioMed Realty snaps up innovation campus site within earshot of pricey and bustling Boston biotech hub

On the short list of the premier biotech hubs in the world, the Boston area has transformed into a home for innovation — and ridiculously high rent. Now, a real estate firm is seeking ...

READ MORE

Paul Hudson faces down French unions in fight to restructure Sanofi

Yesterday

AstraZeneca keeps the ball rolling on Daiichi-partnered Enhertu, picking up 2nd indication in gastric cancer

Yesterday

latest in Pharma

Eli Lilly re-ups diversity pledge, pitching in $30M to venture fund for minority-owned healthcare firms

6 days ago

Amgen tops cost watchdog's price gougers list based on 'unsupported' increases for Enbrel without meaningful data

6 days ago

#JPM21: Albert Bourla prepares Pfizer to settle in to next phase post-Upjohn, but that doesn't mean he's ruling out deals

Last week

What can a 157-year-old pharma giant bring to the table of cell and gene therapies? Quite a bit, Bayer says

Last week

Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO

Last week

see latest stories

R&D channel feed

5 days ago

Gilead partner Arcus earns analysts' plaudits for early pancreatic cancer data that 'exceeded expectations'

Arcus’ small molecule CD73 inhibitor for pancreatic cancer got a standing ovation from analysts who said preliminary data “exceeded expectations”— making waves in a field that’s ...

READ MORE

Can Brett Monia push Ionis beyond Spinraza?

6 days ago

R&D exec faces up to 10 years in prison on charges he stole “thousands” of top secret research documents from ...

Last week

latest in R&D

A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on one last PhIII bid

Last week

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

Last week

With KRAS breakthrough on the horizon, Amgen's David Reese reflects on sotorasib's looming review date and murky future

Last week

Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for combination trial

Last week

Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable

Last week

see latest stories

Outsourcing channel feed

2 weeks ago

Fujifilm's CDMO arm plots massive $2B plant in the US for broad range of therapeutics

Buoyed by interest from major Covid-19 vaccine makers for its viral-vector capabilities, Fujifilm's CDMO arm has looked to rapidly build its US footprint to meet demand. Now, just days ...

READ MORE

Fujifilm's CDMO carves foothold in Boston biotech hub with new HQ focused on viral vectors, gene therapies

3 weeks ago

Amid a busy year and new leadership, Lonza looks to build bioconjugates capacity with Swiss expansion set for 2022

5 weeks ago

latest in Outsourcing

Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant

5 weeks ago

A booming market propels China CRO to a $100M raise. Is an IPO next?

Last month

Continuing rapid expansion, Thermo Fisher says it will add on plasmid DNA manufacturing site in California

Last month

Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion

Last month

Thermo Fisher aims to boost its clinical offerings with German expansion — including cold chain for the Covid-19 effort

Last month

see latest stories

Regulatory channel feed

2 days ago

Poll: Should Joshua Sharfstein or Janet Woodcock lead the FDA from here?

It’s time for a new FDA commissioner to come on board, a rite of passage for Joe Biden’s administration that should help seal the new president's rep on seeking out the experts to lead ...

READ MORE

Pieris finally vaults FDA hold on next-gen solid tumor hunter, clearing the path for mid-stage trial

23 hours ago

FDA hits the brakes on Histogen's knee cartilage therapy, asking for more info on manufacturing process

23 hours ago

latest in Regulatory

FDA guides on Covid-19 considerations in cell and gene therapy

4 hours ago

Bristol Myers Squibb gets review date for Opdivo combo in gastric cancer, looking to overturn Keytruda's 3-year lead

Yesterday

HHS, FDA dispute spills out onto Twitter

Yesterday

Janet Woodcock is in the running for FDA commissioner — what does that mean for the agency's future?

5 days ago

Industry, FDA begin to hammer out PDUFA VII details

6 days ago

see latest stories